Compare IDEXX Laboratories, Inc. (IDXX) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs ProShares Ultra QQQ ETF — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while ProShares Ultra QQQ ETF trades at $92.04. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | QLD | |
|---|---|---|
Market Cap | $46.22B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $766.68 | $100.53 |
52-Week Low | $526.44 | $57.16 |
Enterprise Value | $47.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
QLD, the ProShares Ultra QQQ ETF, trades at $92.32, up 0.75% today, reflecting a bullish technical stance with moving averages signaling strength. The fund offers 2x daily leveraged exposure to the Nasdaq-100 index, having delivered over 10,000% total return since inception. Recent institutional buying includes 180 Wealth Advisors increasing its stake by 29.4% in Q2 2026 (SEC Form 13F filing, August 6, 2026).
Outlook remains tied to tech sector performance, with AI optimism and easing geopolitical tensions cited as tailwinds (Zacks Investment Research, May 29, 2026). Key risks include leveraged ETF decay and volatility, evidenced by a 63.80% historical maximum drawdown. The neutral oscillator reading suggests near-term consolidation may precede further moves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
